slotkoers
Andere beurzen
|
||
- GBX | - |
|
24/06 | Buitenlandse banken richten zich op Zwitserland na overname van Credit Suisse door UBS | RE |
24/06 | NOVARTIS AG : Barclays geeft een verkoopadvies | ZD |
Omzet 2024 * | 49,13 mld. 45,84 mld. | Omzet 2025 * | 51,26 mld. 47,84 mld. | Marktkapitalisatie | 218 mld. 204 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 10,45 mld. 9,75 mld. | Nettowinst (verlies) 2025 * | 11,7 mld. 10,91 mld. | EV/omzet 2024 * | 4,7 x |
Nettoschuld 2024 * | 12,71 mld. 11,86 mld. | Nettoschuld 2025 * | 10,76 mld. 10,04 mld. | EV/omzet 2025 * | 4,47 x |
K/w-verhouding 2024 * |
20,9
x | K/w-verhouding 2025 * |
18,1
x | Werknemers | - |
Dividendrendement 2024 * |
3,42% | Dividendrendement 2025 * |
3,55% | Vrij verhandelbaar | 85,22% |
Recentste transcriptie over NOVARTIS
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 01-01-05 | |
Director of Finance/CFO | 59 | 01-01-03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01-01-13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28-02-20 |
Chairman | 68 | 01-01-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+54,61% | 811 mld. | |
+43,59% | 640 mld. | |
-6,33% | 353 mld. | |
+20,62% | 333 mld. | |
+10,44% | 302 mld. | |
+17,83% | 246 mld. | |
+2,33% | 225 mld. | |
+8,61% | 168 mld. | |
-4,76% | 155 mld. |
- Beurs
- Aandelen
- Koers NOVN
- Koers 0HKE